BMY - Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch | Benzinga
On Wednesday, Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
The results of SEQUOIA-HCM show that treatment with aficamten significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake (pVO2) measured by cardiopulmonary exercise testing (CPET) by at least a square mean difference of 1.74 (1.04 - 2.44) mL/kg/min.
Raymond James notes the management's commentary regarding a "handful" of down titrations due to site LVEF reads at a proportion consistent with the core lab results, and patients were well managed, a key ...